Lymphoma

Adcetris is an antibody-drug that targets a type of lymphoma cell called CD30. It is the first treatment approved by the FDA for fighting Hodgkin lymphoma since 1977, and also the first made to specifically treat anaplastic large cell lymphoma.

Adcetris is the first treatment for fighting Hodgkin lymphoma approved by the FDA since 1977, and the first specifically made to treat anaplastic large cell lymphoma. The drug is marketed by Seattle Genetics of Bothell, Wash.

Researchers at the University of Birmingham have discovered that a modified version of Ecstasy (MDMA) may have great cancer-busting potential, fighting off myeloma, lymphoma, and leukemia.

A government advisory panel unanimously approved an experimental drug, Adcetris, from Bothell, WA.-based drug maker, Seattle Genetics, serving as the company's first commercial drug approved by the U.S. Food and Drug Administration.

J.P. Morgan Securities started coverage of Allos Therapeutics Inc with an overweight rating and a price target of $10, citing upside potential from the company's key drug Folotyn.

Children and young people who survive cancer have a significantly higher risk of developing heart disease as young adults because of the cancer treatment they received, researchers said Wednesday.

Microsoft Corp co-founder Paul Allen has been diagnosed with non-Hodgkin's lymphoma and has begun treatment, a spokesman for his investment company said on Monday.

Some treatments for inflammatory bowel disease increase the risk of infection-related cancers, French scientists said on Monday, but the benefits of the drugs still outweigh the risks.

WASHINGTON - U.S. drug reviewers questioned findings from biotech company Allos Therapeutics Inc (ALTH.O) on the effectiveness of its proposed drug for an aggressive type of lymphoma, documents released on Friday showed.